SCHEMBL31227607

SCHEMBL31227607

COc1c(F)ccc2c(N[C@@H]3CCCN(C(=O)OC(C)(C)C)C3)nccc12

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ PIK3CD O00329 2/20 0.47
▸ PIK3CA P42336 1/20 0.42
▸ USP30 Q70CQ3 1/20 0.42
▸ ANO1 Q5XXA6 1/20 0.41
▸ HDAC4 P56524 1/20 0.41
▸ HDAC6 Q9UBN7 1/20 0.41
▸ BTK Q06187 3/20 0.41
▸ PIM1 P11309 2/20 0.41
▸ PIM2 Q9P1W9 2/20 0.41
▸ PARP1 P09874 1/20 0.41
▸ TRPV3 Q8NET8 1/20 0.41
▸ TRPV1 Q8NER1 1/20 0.40
▸ POLB P06746 1/20 0.40
▸ EGFR P00533 2/20 0.40
▸ ITK Q08881 1/20 0.40
▸ JAK3 P52333 1/20 0.40
▸ ALOX5AP P20292 1/20 0.40
▸ FEN1 P39748 1/20 0.40
▸ ALDH1A1 P00352 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31227178 0.88 PIK3CD (0.47) PIK3CDPIK3CAUSP30HDAC4HDAC6
SCHEMBL31227554 0.87 USP30 (0.48) PIK3CDUSP30ANO1HDAC4HDAC6
SCHEMBL31227628 0.85 PIK3CD (0.44) PIK3CDUSP30ANO1HDAC4HDAC6
SCHEMBL31227738 0.84 PIK3CD (0.47) PIK3CDPIK3CAUSP30ANO1BTK
SCHEMBL31227813 0.83 BTK (0.45) PIK3CDUSP30ANO1HDAC4HDAC6
SCHEMBL21598992 0.82 USP30 (0.50) USP30HDAC4HDAC6BTKPIM1
SCHEMBL31247168 0.82 PIK3CD (0.48) PIK3CDPIK3CAUSP30ANO1HDAC4
SCHEMBL31227846 0.81 PIK3CD (0.49) PIK3CDPIK3CAUSP30BTKPIM1
SCHEMBL31227119 0.80 ANO1 (0.51) PIK3CDPIK3CAUSP30ANO1HDAC4
SCHEMBL31227331 0.80 BTK (0.44) PIK3CDPIK3CAUSP30ANO1HDAC4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240400555-A1 Compounds, Compositions and Methods for Attenuation of Mammalian Translation of C-MYC or N-MYC Proteins of the MYC Proto-Oncogene Family of BHLH Transcription Factors INITIAL THERAPEUTICS, INC. (US) 2024-12-05 — — US disclosed
WO-2024226875-A2 COMPOUNDS, COMPOSITIONS AND METHODS FOR ATTENUATION OF MAMMALIAN TRANSLATION OF C-MYC OR N-MYC PROTEINS OF THE MYC PROTO-ONCOGENE FAMILY OF BHLH TRANSCRIPTION FACTORS INITIAL THERAPEUTICS, INC. (US) 2024-10-31 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240400555-A1 Compounds, Compositions and Methods for Attenuation of Mammalian Translation of C-MYC or N-MYC Proteins of the MYC Proto-Oncogene Family of BHLH Transcription Factors MYCBP, MYC, MYCBP2 PIK3CD 3846/4885PIK3CA 3654/4885USP30 3093/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback